| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 86.62K | 125.43K | 207.44K | 117.07K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -86.62K | -125.43K | -207.44K | -117.07K | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -0.45% | -0.65% | 0.44% | 1% | - | - | - |
| Operating Expenses | 4.84M | 11.9M | 6.62M | 2.36M | 14.65M | 17.62M | 27.85M | 38.83M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.48M | 5.1M | 3.1M | 1.27M | 6.97M | 3.99M | 7.48M | 15.71M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 3.36M | 6.8M | 3.52M | 1.09M | 7.59M | 13.63M | 20.36M | 23.12M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 1.74K | 0 | 87.47K | 0 | 0 | 0 |
| Operating Income | -4.93M | -12.02M | -6.82M | -2.47M | -14.65M | -17.62M | -27.85M | -38.83M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -1.44% | 0.43% | 0.64% | -4.92% | -0.2% | -0.58% | -0.39% |
| EBITDA | -4.84M | -11.9M | -6.62M | -2.36M | -14.56M | -17.47M | -27.69M | -38.59M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -1.46% | 0.44% | 0.64% | -5.18% | -0.2% | -0.59% | -0.39% |
| D&A (Non-Cash Add-back) | 86.62K | 125.43K | 207.44K | 117.07K | 87.47K | 147.89K | 155.53K | 246.95K |
| EBIT | -5.02M | -14.64M | -5.93M | -2.13M | -17.31M | -18.01M | -27.76M | -36.15M |
| Net Interest Income | -52.48K | -141.07K | -1.45M | -1.88M | -965.44K | -551.06K | -307.2K | 800.11K |
| Interest Income | 330 | 1.11K | 12.04K | 427 | 51.55K | 431.8K | 862.97K | 1.67M |
| Interest Expense | 52.81K | 142.17K | 1.46M | 1.88M | 1.02M | 982.86K | 1.17M | 867.99K |
| Other Income/Expense | -145.22K | -2.76M | -615.22K | -1.55M | -3.68M | -1.37M | -1.08M | 1.81M |
| Pretax Income | -5.07M | -14.79M | -7.44M | -4.02M | -18.33M | -18.99M | -28.93M | -37.02M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 36.42K | 2.59K |
| Effective Tax Rate % | 0.86% | 0.89% | 0.99% | 1% | 0.98% | 0.97% | 0.98% | 0.99% |
| Net Income | -4.38M | -13.19M | -7.37M | -4.01M | -18.03M | -18.49M | -28.22M | -36.67M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -2.01% | 0.44% | 0.46% | -3.5% | -0.03% | -0.53% | -0.3% |
| Net Income (Continuing) | -5.07M | -14.79M | -7.44M | -4.02M | -18.33M | -18.99M | -28.97M | -37.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -871.66K | -376.02K | -440.45K | -453.89K | -833.84K | -783.49K | -1.32M | -1.57M |
| EPS (Diluted) | -0.34 | -1.03 | -0.56 | -0.31 | -1.61 | -0.96 | -1.17 | -0.76 |
| EPS Growth % | - | -2.03% | 0.46% | 0.45% | -4.19% | 0.4% | -0.22% | 0.35% |
| EPS (Basic) | -0.34 | -1.03 | -0.56 | -0.31 | -1.61 | -0.96 | -1.17 | -0.76 |
| Diluted Shares Outstanding | 12.87M | 12.87M | 12.87M | 12.87M | 14.24M | 19.29M | 24.15M | 33.93M |
| Basic Shares Outstanding | 12.87M | 12.87M | 12.87M | 12.87M | 14.24M | 19.29M | 24.15M | 33.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.42M | 2.47M | 2.64M | 1.14M | 30.6M | 25.17M | 19.8M | 34.44M |
| Cash & Short-Term Investments | 3.99M | 823.48K | 1.16M | 150.13K | 29.9M | 24.73M | 19.34M | 33.1M |
| Cash Only | 3.99M | 823.48K | 1.16M | 150.13K | 20.89M | 24.73M | 19.34M | 33.1M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 9.01M | 0 | 0 | 0 |
| Accounts Receivable | 1.04M | 1.09M | 0 | 0 | 0 | 0 | 190.61K | 228.87K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 120.82K | 166.75K | 1.35M | 620.61K | 429.72K | 121.47K | 0 | 0 |
| Total Non-Current Assets | 419.44K | 435.47K | 646.21K | 315.34K | 620.44K | 721.98K | 463.15K | 505.68K |
| Property, Plant & Equipment | 419.44K | 435.47K | 646.21K | 315.34K | 589.07K | 718.61K | 456.25K | 424.92K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 31.37K | 3.37K | 6.9K | 80.76K |
| Total Assets | 5.84M | 2.91M | 3.29M | 1.45M | 31.22M | 25.89M | 20.27M | 34.94M |
| Asset Turnover | - | - | - | - | - | - | - | - |
| Asset Growth % | - | -0.5% | 0.13% | -0.56% | 20.48% | -0.17% | -0.22% | 0.72% |
| Total Current Liabilities | 730.68K | 14.34M | 20.67M | 22.54M | 2.27M | 4.14M | 19.37M | 3.1M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 3.79M | 11.63M | 12.52M | 94.92K | 107.53K | 10.4M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 440.65K | 5.33M | 6.8M | 6.94M | 5.01K | 21.66K | 858.63K | 1.49M |
| Current Ratio | 7.42x | 0.17x | 0.13x | 0.05x | 13.49x | 6.08x | 1.02x | 11.10x |
| Quick Ratio | 7.42x | 0.17x | 0.13x | 0.05x | 13.49x | 6.08x | 1.02x | 11.10x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.13K | 0 | 749.35K | 574.97K | 9.84M | 11.99M | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 9.7M | 11.92M | 0 | 0 |
| Capital Lease Obligations | 4.08K | 0 | 251.19K | 198.66K | 137.75K | 69.46K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.05K | 0 | 498.15K | 376.31K | 0 | 0 | 0 | 0 |
| Total Liabilities | 735.82K | 14.34M | 21.42M | 23.12M | 12.1M | 16.13M | 19.37M | 3.1M |
| Total Debt | 12.47K | 3.79M | 11.94M | 12.77M | 9.99M | 12.17M | 10.45M | 71.86K |
| Net Debt | -3.98M | 2.97M | 10.78M | 12.62M | -10.9M | -12.56M | -8.89M | -33.03M |
| Debt / Equity | 0.00x | - | - | - | 0.52x | 1.25x | 11.71x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -93.28x | -84.56x | -4.66x | -1.32x | -14.40x | -17.92x | -23.80x | -44.74x |
| Total Equity | 5.11M | -11.44M | -18.13M | -21.66M | 19.12M | 9.76M | 892.33K | 31.84M |
| Equity Growth % | - | -3.24% | -0.59% | -0.19% | 1.88% | -0.49% | -0.91% | 34.68% |
| Book Value per Share | 0.40 | -0.89 | -1.41 | -1.68 | 1.34 | 0.51 | 0.04 | 0.94 |
| Total Shareholders' Equity | 5.98M | -11.06M | -17.69M | -21.21M | 19.95M | 10.54M | 2.22M | 33.4M |
| Common Stock | 23.59M | 23.55M | 23.55M | 23.8M | 77.65M | 96.13M | 92.91M | 116.36M |
| Retained Earnings | -20.11M | -40.02M | -47.2M | -51.2M | -74.26M | -104.63M | -105.5M | -131M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 16.56M | -3.77M | -2.71M | -4.16M |
| Minority Interest | -871.66K | -376.02K | -440.45K | -453.89K | -833.84K | -783.49K | -1.32M | -1.57M |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.3M | -8.32M | -5.17M | -403.78K | -11.58M | -14.4M | -20.75M | -29.99M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -0.57% | 0.38% | 0.92% | -27.67% | -0.24% | -0.44% | -0.45% |
| Net Income | -5M | -14.83M | -7.18M | -4M | -18.18M | -18.99M | -28.97M | -25.74M |
| Depreciation & Amortization | 85.38K | 125.83K | 201.94K | 116.81K | 88.17K | 147.89K | 155.53K | 171.72K |
| Stock-Based Compensation | 162.82K | 2.92M | 544.95K | 228.68K | 0 | 1.43M | 1.41M | 3.22M |
| Deferred Taxes | 0 | 291.05K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 51.17K | 2.08M | 1.09M | 2.52M | 6.68M | 1.5M | 1.3M | -880.5K |
| Working Capital Changes | -599.39K | 1.1M | 167.54K | 730.59K | -167.16K | 1.51M | 5.35M | -6.76M |
| Change in Receivables | -340.22K | -208.58K | 135.27K | 727.69K | 150.92K | 230.48K | -103.71K | -101.39K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 1.32M | 577.91K | -714.88K |
| Cash from Investing | -314.69K | -141.86K | -1.9M | 24.62K | -11.42M | 9.83M | -73.38K | -75.16K |
| Capital Expenditures | -314.69K | -141.86K | -9.48K | 0 | -341.28K | -235.55K | -73.38K | -104.23K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -1.89M | 24.62K | -3.97M | 242 | 0 | 29.07K |
| Cash from Financing | 9.47M | 5.3M | 7.4M | -626.64K | 39.46M | 10.8M | 21.08M | 45.78M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 2.62M | 3.02M | 474.05K | -69.33K | 306.77K | 5.27M | 363.06K |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -5.61M | -8.46M | -5.18M | -403.78K | -11.92M | -14.63M | -20.82M | -30.1M |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -0.51% | 0.39% | 0.92% | -28.51% | -0.23% | -0.42% | -0.45% |
| FCF per Share | -0.44 | -0.66 | -0.40 | -0.03 | -0.84 | -0.76 | -0.86 | -0.89 |
| FCF Conversion (FCF/Net Income) | 1.21x | 0.63x | 0.70x | 0.10x | 0.64x | 0.78x | 0.74x | 0.82x |
| Interest Paid | 0 | 0 | 436.44K | 116.06K | 0 | 0 | 0 | 393.74K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -85.79% | - | - | - | -94.31% | -128.06% | -529.9% | -224.1% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -488.04% | - | - |
| Debt / Equity | 0.00x | - | - | - | 0.52x | 1.25x | 11.71x | 0.00x |
| Interest Coverage | -93.28x | -84.56x | -4.66x | -1.32x | -14.40x | -17.92x | -23.80x | -44.74x |
| FCF Conversion | 1.21x | 0.63x | 0.70x | 0.10x | 0.64x | 0.78x | 0.74x | 0.82x |
Eupraxia Pharmaceuticals Inc. (EPRX) grew revenue by 0.0% over the past year. Growth has been modest.
Eupraxia Pharmaceuticals Inc. (EPRX) reported a net loss of $41.2M for fiscal year 2024.
Eupraxia Pharmaceuticals Inc. (EPRX) has a return on equity (ROE) of -224.1%. Negative ROE indicates the company is unprofitable.
Eupraxia Pharmaceuticals Inc. (EPRX) had negative free cash flow of $25.2M in fiscal year 2024, likely due to heavy capital investments.